Evidence map›Paper›PMID 36351892›Full record

ArticleTranslational psychiatry2022

Comparative serum proteomic analysis of a selected protein panel in individuals with schizophrenia and bipolar disorder and the impact of genetic risk burden on serum proteomic profiles.

Mojtaba Oraki Kohshour, Nirmal R Kannaiyan, August Jernbom Falk, Sergi Papiol, Urs Heilbronner, Monika Budde, Janos L Kalman, Eva C Schulte, Marcella Rietschel, Stephanie Witt and 12 more

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 6 countries.

Mojtaba Oraki KohshourInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-1357-2636
Nirmal R KannaiyanDepartment of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-7408-6842
August Jernbom FalkDepartment of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.ORCID 0000-0002-7773-1851
Sergi PapiolInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0001-9366-8728
Urs HeilbronnerInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0001-7135-762X
Monika BuddeInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0001-7301-9157
Janos L KalmanInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0003-0930-4214
Eva C SchulteInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0003-3105-5672
Marcella RietschelDepartment of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID 0000-0002-5236-6149
Stephanie WittDepartment of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID 0000-0002-1571-1468
Andreas J ForstnerInstitute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany.ORCID 0000-0002-1876-6368
Stefanie Heilmann-HeimbachInstitute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany.ORCID 0000-0003-1057-465X
Markus M NöthenInstitute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany.
Carsten SpitzerDepartment of Psychosomatic Medicine and Psychotherapy, University Medical Center Rostock, Rostock, Germany.
Berend MalchowDepartment of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
Thorsten MüllerInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.
Jens WiltfangDepartment of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0003-1492-5330
Peter FalkaiDepartment of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
Andrea SchmittDepartment of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
Moritz J RossnerDepartment of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0002-0667-3420
Peter NilssonDepartment of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.ORCID 0000-0002-4657-8532
Thomas G SchulzeInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany. Thomas.Schulze@med.uni-muenchen.de.
LMU Klinikum · DELudwig-Maximilians-Universität München · DEUniversity of Bonn · DEHeidelberg University · DEScience for Life Laboratory · SEAhvaz Jundishapur University of Medical Sciences · IRGerman Center for Neurodegenerative Diseases · DEJohns Hopkins University · USUniversidade de São Paulo · BRUniversitätsmedizin Göttingen · DEUniversity of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diagnostic criteria for schizophrenia (SCZ) and bipolar disorder (BD) are based on clinical assessments of symptoms. In this pilot study, we applied high-throughput antibody-based protein profiling to serum samples of healthy controls and individuals with SCZ and BD with the aim of identifying differentially expressed proteins in these disorders. Moreover, we explored the influence of polygenic burden for SCZ and BD on the serum levels of these proteins. Serum samples from 113 individuals with SCZ and 125 with BD from the PsyCourse Study and from 44 healthy controls were analyzed by using a set of 155 antibodies in an antibody-based assay targeting a selected panel of 95 proteins. For the cases, genotyping and imputation were conducted for DNA samples and SCZ and BD polygenic risk scores (PRS) were calculated. Univariate linear and logistic models were used for association analyses. The comparison between SCZ and BD revealed two serum proteins that were significantly elevated in BD after multiple testing adjustment: "complement C9" and "Interleukin 1 Receptor Accessory Protein". Moreover, the first principal component of variance in the proteomics dataset differed significantly between SCZ and BD. After multiple testing correction, SCZ-PRS, BD-PRS, and SCZ-vs-BD-PRS were not significantly associated with the levels of the individual proteins or the values of the proteome principal components indicating no detectable genetic effects. Overall, our findings contribute to the evidence suggesting that the analysis of circulating proteins could lead to the identification of distinctive biomarkers for SCZ and BD. Our investigation warrants replication in large-scale studies to confirm these findings.

Indexed as

Bipolar DisorderSchizophreniaGenetic Predisposition to DiseaseHumansPilot ProjectsProteomicsRisk Factors

Identifiers

PMID36351892
PMCPMC9646817
OpenAlexW4308738702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.